{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:39:07Z","timestamp":1792618747276,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100023885","name":"All of Us Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.09.013","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:15:00Z","timestamp":1790694900000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors: A Real-World Active Comparator Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9625-0924","authenticated-orcid":false,"given":"Valentin","family":"Milanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"360","key":"10.1016\/j.eprac.2026.09.013_bib1","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: united States, 2017-2018","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"11","key":"10.1016\/j.eprac.2026.09.013_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2026.09.013_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.013_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.eprac.2026.09.013_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.013_bib8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.013_bib9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.013_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.09.013_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.eprac.2026.09.013_bib12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.eprac.2026.09.013_bib13","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.013_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u2018All of Us\u2019 research program","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.09.013_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.013_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.eprac.2026.09.013_bib18","author":"Greifer"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.013_bib19","first-page":"7","article-title":"Diagnostic checking in regression relationships","volume":"2","author":"Zeileis","year":"2002","journal-title":"R News"},{"key":"10.1016\/j.eprac.2026.09.013_bib20","author":"Arel-Bundock"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.013_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eprac.2026.09.013_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"209","key":"10.1016\/j.eprac.2026.09.013_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.013_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00125-019-05040-3","article-title":"Sex differences in metabolic regulation and diabetes susceptibility","volume":"63","author":"Tramunt","year":"2020","journal-title":"Diabetologia"},{"issue":"21","key":"10.1016\/j.eprac.2026.09.013_bib25","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1001\/jama.2016.6458","article-title":"Trends in obesity among adults in the United States, 2005 to 2014","volume":"315","author":"Flegal","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.013_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.013_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40618-025-02792-1","article-title":"Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study","volume":"49","author":"le Roux","year":"2026","journal-title":"J Endocrinol Invest"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:51Z","timestamp":1792616451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26011572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S1530891X26011572"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.013","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors: A Real-World Active Comparator Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}